JD

Jennie Daisak

Vice President at Bain Capital

New York City Metropolitan Area

Overview 

Jennie Daisak is the Vice President at Bain Capital Life Sciences in New York City, specializing in investing in various sectors including Pharmaceuticals, BioTech, and Health IT. With a background in finance and biology, she has excelled in her career, having worked at prestigious institutions like JPMorgan Chase & Co. and The Children's Hospital of Philadelphia. Jennie Daisak's career highlights include her role as a Vice President at Bain Capital, where she focuses on investing in Series B, Series A, and Seed stage companies in the life sciences sector. Her educational background includes a Bachelor of Science in Applied Economics from The Wharton School and a Bachelor of Arts in Biology from the University of Pennsylvania.

Work Experience 

  • Vice President

    2024 - Current

  • Associate

    2021 - 2024

Bain Capital is an alternative investment firm specializing in private equity, venture capital, and credit products.

  • Healthcare Investment Banking Analyst

    2019 - 2021

Morgan Health is the healthcare investment arm of JPMorgan Chase.

  • Healthcare Investment Banking Summer Analyst

    2018 - 2018

Morgan Health is the healthcare investment arm of JPMorgan Chase.

  • Clinical Research Assistant

    2016 - 2018

    • Clinical Research Assistant for Dr. Susan Rheingold, an attending physician studying relapsed leukemia at CHOP. • Retrieved and analyzed data to investigate the clinical significance of a novel gene fusion in pediatric patients.

The Children's Hospital of Philadelphia offers hospital devoted exclusively to caring for children.

Raised $28,350,000.00 from Advanced Research Projects Agency for Health, Hyundai Hope On Wheels, The Wyss Foundation, Pediatric Cancer Foundation, Gilbert Family Foundation, Hyundai Hope On Wheels, American Heart Association and Hyundai Hope On Wheels.

  • Lead Discovery and Optimization Intern

    2017 - 2017

    • Identified new small molecule targets for combination immuno-oncology treatments using gene profiling in fulfillment of the Life Sciences and Management Program’s required scientific research internship. • Performed statistical analysis on data sets with over ten thousand data points and presented findings to BMS leadership. • Gained insight into BMS business model through exposure to several business areas and top executives.

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.

  • Research Assistant

    2014 - 2014

    • Performed experiments and analyzed data to explore the tumor suppressive functions of the urea cycle in renal cell carcinoma in the lab of Dr. Celeste Simon • Co-authored a paper published in Cell Metabolism: Ochocki et al., Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity, Cell Metabolism (2018), https://doi.org/10.1016/j.cmet.2018.04.009

Articles About Jennie

Relevant Websites